1. Predictive and sensitive biomarkers for thyroid dysfunctions during treatment with immune‐checkpoint inhibitors
- Author
-
Takashi Akamizu, Chiaki Kurimoto, Yasushi Furukawa, Masatoshi Jinnin, Hidefumi Inaba, Hiroshi Iwakura, Shuhei Morita, Ken Takeshima, Yuki Yamamoto, Hiroaki Akamatsu, Hiroyuki Ariyasu, Hiroki Yamaue, Yoko Ueda, Shinsuke Uraki, Atsushi Hayata, Masahiro Katsuda, Shimpei Yamashita, and Isao Hara
- Subjects
Male ,0301 basic medicine ,Oncology ,Cancer Research ,endocrine system diseases ,thyroid dysfunction ,medicine.medical_treatment ,Programmed Cell Death 1 Receptor ,Thyroid Gland ,thyroglobulin ,Thyroiditis ,Mice ,Basic and Clinical Immunology ,0302 clinical medicine ,Neoplasms ,cytokine ,Prospective Studies ,Aged, 80 and over ,Thyroid ,General Medicine ,Middle Aged ,Anti-thyroid autoantibodies ,immune‐related adverse events ,medicine.anatomical_structure ,030220 oncology & carcinogenesis ,Cytokines ,Female ,Original Article ,immunotherapy ,Thyroid function ,endocrine system ,medicine.medical_specialty ,Autoimmune thyroiditis ,03 medical and health sciences ,Internal medicine ,medicine ,Animals ,Humans ,Immunologic Factors ,Endocrine system ,Aged ,Autoantibodies ,business.industry ,Thyroiditis, Autoimmune ,Autoantibody ,Original Articles ,medicine.disease ,Thyroid Diseases ,Disease Models, Animal ,030104 developmental biology ,Thyroglobulin ,business ,Biomarkers - Abstract
Immune‐related adverse events (irAEs) are often seen during immune‐checkpoint inhibitor (ICI) treatment of various malignancies. Endocrine irAEs including thyroid dysfunctions are the most common irAEs, but their biomarkers remain unclear. In order to identify individuals who are susceptible to thyroid irAE for earlier diagnosis and appropriate follow‐up, the current study is aimed to investigate biomarkers of thyroid irAE. Herein, patients with advanced malignant diseases who received ICIs treatment were prospectively studied. Clinical and laboratory examination, thyroid function, and autoantibodies were evaluated at baseline, and every 4 wk after first treatment with ICIs. Cytokines/chemokines were measured at baseline and at 4 wk. In vivo effects of ICIs on experimental autoimmune thyroiditis were evaluated. Twenty‐six patients with malignant diseases who received ICIs treatment were enrolled in the study. Patients were divided into two groups: those who developed thyroid irAE, and those without irAEs. Comparing the two groups, early increase (≤4 wk) in serum thyroglobulin (Tg) levels and thyroid autoantibodies was seen in thyroid irAE (P
- Published
- 2020